Menus Subscribe Search

Follow us


Genes Are Us

cleopatra

Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

Elizabeth Taylor, My Great-Grandpa, and the Future of Antibiotics

• June 27, 2014 • 4:00 AM

Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

While it’s not clear whether or not they worked for the Cleopatra star over a half-century ago, phage treatments could help solve the growing problem of antibiotic resistance.

In March of 1961, Elizabeth Taylor was in London filming her next blockbuster, Cleopatra, when she fell ill with pneumonia. She underwent an emergency tracheotomy, and for days the press followed every development in her increasingly dire situation. On March 7, a Philadelphia-area newspaper reported that a local company, Delmont Laboratories, had put several doses of an unusual antibacterial treatment on the next jet to London at the request of Taylor’s doctors. With a touch of community pride, the paper reported that the treatment, “staphylococcus bacteriophage lysate,” was exclusively manufactured by Delmont Laboratories, and that “Christopher Roos, laboratory director and formerly senior bacteriologist for Sharpe and Dohme, played a major part in its development.”

It’s not clear what impact the treatment had on Elizabeth Taylor, but Christopher Roos, my great-grandfather, didn’t doubt its efficacy. My mother recalls that during her childhood visits to his house, he would treat her colds with a dose, administered as a nasal spray. Staphylococcus bacteriophage lysate is a form of antibacterial therapy based on phages, viruses that are the natural predators of bacteria. Discovered early in the 20th century, decades before modern antibiotics, phages have an obvious therapeutic potential that doctors and scientists were quick to explore. In the 1930s and ’40s, bacteriophage preparations were manufactured by major drug companies like Eli Lilly, and used to treat everything from cholera to wound infections.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. The number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up.

But the hype got a bit ahead of the science. The biology of these viruses was not well understood, and phage treatments were difficult to prepare consistently. The effectiveness of the treatments varied widely, and while there were some clinical studies of phage therapy, many weren’t particularly rigorous by rapidly modernizing, post-World War II standards. In the mid-1940s, penicillin, cheap and obviously effective, began to be mass-produced in the U.S. By the time that Liz Taylor’s doctors called my great-grandfather, phage therapy was on the wane. Knowing that, the story sounds like the familiar scenario of the celebrity doctor who peddles some unproven alternative treatment to his famous patient.

But that characterization isn’t accurate. Despite the lack of rigor in the early studies, there is a long record of substantial evidence showing that phage therapy holds genuine promise. After phage therapy was superseded by antibiotics in the West, researchers in the Soviet Union and Eastern Europe—where antibiotics weren’t as readily available—continued to work on phage therapy, with encouraging results. Some occasional studies continued in the U.S. and Western Europe as well. And now, phage therapy is in the limelight again, drawing the interest of researchers, governments, and biotech companies.

What changed? As my Washington University colleague Jeffrey Gordon and his co-workers wrote, we’re experiencing “the incipient rise of a phage biology renaissance,” thanks to modern DNA analysis technologies. Discovered before we knew that genes were made of DNA, we now know that phages are highly efficient gene-delivery machines. They inject their genomes into bacteria, hijack the bacterial machinery to make new DNA copies of themselves, and repackage those copies into protein capsules, bursting open the bacterial cell in the process. The capsules then diffuse away in search of new bacterial prey. By scouring oceans, soil, and our own bodies for phage DNA, researchers have discovered an enormous world of viruses with a tremendous bacterial-killing capability—according to one review, “phage predation destroys an estimated half of the world bacteria population every 48 hours.” The diversity of the world’s bacteriophages is an essentially inexhaustible source that we can trawl for potential anti-bacterial treatments, with the aid of today’s highly effective biotechnological tools. And researchers like Gordon and his lab members are exploring how phages operate in their natural habitats, such as the human gut.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. As the Centers for Disease Control reported last year, the number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up. Two million people acquire antibiotic-resistant infections each year in the U.S., leading to over $20 billion in health care costs. And antibiotics themselves pose a major burden, accounting for 20 percent of all emergency room visits for adverse drug events.

Phage therapy has the potential to avoid all of these problems. While bacteria can become resistant to any one strain of phage, there are many different phage strains out there that could be combined into an effective, multi-strain cocktail treatment. And unlike chemical antibiotics, phages have their own genomes that can evolve to circumvent the defenses of resistant bacteria. Phage therapy also would not destroy the important community of healthy bacteria in our guts. Antibiotics wipe out these healthy gut bacteria, leaving people vulnerable to opportunistic infections by Clostridium difficile, a bacteria that the CDC reports is responsible for 14,000 deaths each year in the U.S.

The need is there, but will phage therapy actually work in humans? The answer is a cautious yes. The biomedical research community is certainly ready to try, bringing new funding, technology, and rigor to this old-fashioned approach to infections. A clinical trial of phage therapy for infected burn wounds is underway in Europe. The FDA has already approved phages to kill contaminating bacteria in food, and phage treatments for infections are being tested for efficacy in some animal studies, as well as for safety in a few human studies (PDF). Phage therapy may or may not become the major solution to our crisis of antibiotic resistance, but it is very likely that we’ll soon see a variety of limited but successful applications of phage therapy in humans.

Delmont’s product was a federally-approved drug in the 1950s, but as the FDA revised its approach to regulation in later decades, the small company struggled (PDF), and, in the 1990s, it stopped selling its bacteriophage treatments for human use. The company continues to make a USDA-licensed phage therapy to treat recalcitrant skin infections in dogs. When my great-grandfather sent those doses of phage lysate express to Liz Taylor, the time wasn’t quite right for phage therapy, scientifically or economically. But times have changed, and this old-fashioned treatment may become cutting-edge.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

September 22 • 4:00 PM

The Overly Harsh and Out-of-Date Law That’s So Difficult on Debtors

A 1968 federal law allows collectors to take 25 percent of debtors’ wages, or every penny in their bank accounts.


September 22 • 2:00 PM

NFL Players Are More Law Abiding Than Average Men

According to records kept by USA Today, 2.53 percent of players are arrested in any given year.


September 22 • 12:00 PM

Freaking Out About Outliers: When the Polls Are Way Off

The idea of such a small number of people being used to predict how millions will vote sometimes irks observers, but it’s actually a very reliable process—most of the time.


September 22 • 10:00 AM

The Imagined Sex Worker

The stigma against black sex workers can reinforce stigmas against all black women and all sex workers.


September 22 • 9:54 AM

All-Girls Schools Don’t Make Girls More Competitive

Parents, not educational setting, may be the key.


September 22 • 8:00 AM

The NFL, the Military, and the Problem With Masculine Institutions

Both the NFL and the U.S. military cultivate and reward a form of hyper-violent masculinity. The consequences of doing so have never been more obvious.


September 22 • 6:00 AM

Zombies in the Quad: The Trouble With Elite Education

William Deresiewicz’s new book, Excellent Sheep, is in part, he says, a letter to his younger, more privileged self.


September 22 • 4:02 AM

You’re Going to Die! So Buy Now!

New research finds inserting reminders of our mortality into advertisements is a surprisingly effective strategy to sell products.



September 19 • 4:00 PM

In Your Own Words: What It’s Like to Get Sued Over Past Debts

Some describe their surprise when they were sued after falling behind on medical and credit card bills.



September 19 • 1:26 PM

For Charitable Products, Sex Doesn’t Sell

Sexy women may turn heads, but for pro-social and charitable products, they won’t change minds.


September 19 • 12:00 PM

Carbon Taxes Really Do Work

A new study shows that taxing carbon dioxide emissions could actually work to reduce greenhouse gases without any negative effects on employment and revenues.


September 19 • 10:00 AM

Why the Poor Remain Poor

A follow-up to “How Being Poor Makes You Poor.”


September 19 • 9:03 AM

Why Science Won’t Defeat Ebola

While science will certainly help, winning the battle against Ebola is a social challenge.


September 19 • 8:00 AM

Burrito Treason in the Lone Star State

Did Meatless Mondays bring down Texas Agriculture Commissioner Todd Staples?


September 19 • 7:31 AM

Savor Good Times, Get Through the Bad Ones—With Categories

Ticking off a category of things to do can feel like progress or a fun time coming to an end.


September 19 • 6:00 AM

The Most Untouchable Man in Sports

How the head of the governing body for the world’s most popular sport freely wields his wildly incompetent power.


September 19 • 4:00 AM

The Danger of Dining With an Overweight Companion

There’s a good chance you’ll eat more unhealthy food.



September 18 • 4:00 PM

Racial Disparity in Imprisonment Inspires White People to Be Even More Tough on Crime

White Americans are more comfortable with punitive and harsh policing and sentencing when they imagine that the people being policed and put in prison are black.



September 18 • 2:00 PM

The Wages of Millions Are Being Seized to Pay Past Debts

A new study provides the first-ever tally of how many employees lose up to a quarter of their paychecks over debts like unpaid credit card or medical bills and student loans.


September 18 • 12:00 PM

When Counterfeit and Contaminated Drugs Are Deadly

The cost and the crackdown, worldwide.


September 18 • 10:00 AM

How Do You Make a Living, Molly Crabapple?

Noah Davis talks to Molly Crapabble about Michelangelo, the Medicis, and the tension between making art and making money.


Follow us


All-Girls Schools Don’t Make Girls More Competitive

Parents, not educational setting, may be the key.

For Charitable Products, Sex Doesn’t Sell

Sexy women may turn heads, but for pro-social and charitable products, they won't change minds.

Carbon Taxes Really Do Work

A new study shows that taxing carbon dioxide emissions could actually work to reduce greenhouse gases without any negative effects on employment and revenues.

Savor Good Times, Get Through the Bad Ones—With Categories

Ticking off a category of things to do can feel like progress or a fun time coming to an end.

How to Build a Better Election

Elimination-style voting is harder to fiddle with than majority rule.

The Big One

One in three tourists to Jamaica reports getting harassed; half of them are hassled to buy drugs. September/October 2014 new-big-one-4

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.